Interim Results

AI SummaryClose X

Cizzle Biotechnology Holdings PLC reported interim results for the six months ended 30 June 2026, highlighting the successful accreditation of its CIZ1B Biomarker Blood-Test for Lung Cancer in the U.S. under CLIA, marking the start of its commercialization phase. The company also secured new patents in the U.S. and Canada, strengthening its intellectual property. Aggregate guaranteed minimum royalty receipts increased to approximately US$5.9 million due to a seven-year renewal of a licensing agreement. The period saw a loss of £329,000, an improvement from the prior year's £368,000 loss, and the company received £350,000 through convertible loan notes. Cash balances stood at £81,000 as of 30 June 2026.

Disclaimer*

UK 100

Latest directors dealings